Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
August 2016
-
Media Release
AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment
New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving… -
Media Release
FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases
Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is approved for all indications included in the reference product's… -
Media Release
Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
13th International Biotechnology Leadership Camp focuses on potential of new technologies to fundamentally transform biomedical research and the pharmaceutical business Interactive program… -
Media Release
Experten diskutieren am Novartis International BioCamp neue Technologien im Gesundheitsbereich
Im Zentrum des 13. International Biotechnology Leadership Camp steht das Potenzial neuer Technologien, die biomedizinische Forschung und die Pharmabranche grundlegend zu verändern Das interaktive… -
Media Release
Novartis convie plusieurs experts au Novartis International BioCamp afin de discuter des nouvelles technologies en matière de santé
La 13e édition de l'International Biotechnology Leadership Camp explore les nouvelles technologies susceptibles de révolutionner la recherche biomédicale et l'industrie pharmaceutique. Un programme… -
Featured News
Nurturing the next generation of scientists
Novartis internships help build research capabilities in developing countries.
-
Featured News
Students take on the challenges of digital medicine
Novartis BioCamp gives students new perspectives on healthcare challenges.
-
In search of the differences that make the difference
Ambitious scientist accelerates research into African genomic diversity and health challenges with internship
-
Media Release
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression… -
Featured News
Taking action for psoriasis patients: the WHO psoriasis resolution
The World Health Organization (WHO) passed a resolution on psoriasis that creates an urgent call to action for the international community.
-
In The News
Reigniting a passion for science
How two years in a Novartis lab changed Johnny Castillo's life -
Stifling danger signals in rheumatoid arthritis
Blocking an inflammatory pathway may offer a new way to treat autoimmune disease.
Pagination
- ‹ Previous page
- 1
- …
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- …
- 154
- › Next page
Test disclaimer...!!!